Denosumab increased bone mineral density but caused marked serum calcium fluctuations in a patient undergoing peritoneal dialysis
CEN Case Reports · 30.06.2026 · 15 (4)
DOI: 10.1007/s13730-026-01142-1 ↗Kurz gefasst
Fallbericht in der Zeitschrift CEN Case Reports, online erschienen am 30.06.2026. Verfasst von Shunsuke Yamada und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, J…. Hauptthemen laut MEDLINE: Denosumab, Bone Density, Calcium, Peritoneal Dialysis. Die Arbeit nennt 4 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Denosumab is increasingly used to treat osteoporosis in patients with advanced kidney disease, but clinically significant disturbances in calcium homeostasis remain a major concern. We report a peritoneal dialysis (PD) case in which denosumab administration was followed by pronounced calcium fluctuations requiring medication management. A 56-year-old woman with end-stage kidney disease due to lupus nephritis, receiving prednisolone (5 mg/day), had been on continuous ambulatory PD (1.5-L exchanges three times daily) for 5 years. Baseline intact parathyroid hormone was 176 pg/mL. Osteoporosis was confirmed by dual-energy X-ray absorptiometry (lumbar spine 68% and femoral neck 58% of the young adult mean [YAM]). Denosumab 60 mg was administered, and BMD increased within 10 months to 78% YAM at the lumbar spine and 77% YAM at the femoral neck (same facility, identical DXA equipment). To mitigate hypocalcemia, dialysate calcium was pre-emptively increased to two 3.5-mEq/L and one 2.5-mEq/L bags per day (albumin-corrected calcium 9.5 mg/dL at dosing). Nonetheless, symptomatic hypocalcemia developed (nadir 7.8 mg/dL on day 7), prompting escalation to three 3.5-mEq/L bags with intensified vitamin D therapy and calcium supplementation. Serum calcium then overshot, peaking at 13.8 mg/dL on day 29; therapy was de-escalated and calcium stabilized. This case highlights that while daily dialysate calcium exposure in PD may buffer early hypocalcemia, concurrent escalation of dialysate calcium, vitamin D therapy, and calcium supplementation can precipitate overshoot hypercalcemia. Frequent monitoring and staged, stepwise prescription changes during the first month after denosumab are essential. Standardized PD-specific post-denosumab calcium management protocols are urgently needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. yamada.shunsuke.944@m.kyushu-u.ac.jp.
- Division of Kidney Care Unit, Kyushu University Hospital, Fukuoka, Japan. yamada.shunsuke.944@m.kyushu-u.ac.jp.
- Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
ORCID-Profile: Shunsuke Yamada
Zitieren
APA
Yamada, S., Enomoto, S., Matsuo, K., Sonezaki, Y., & Torisu, K. (2026). Denosumab increased bone mineral density but caused marked serum calcium fluctuations in a patient undergoing peritoneal dialysis. CEN Case Reports, 15(4). https://doi.org/10.1007/s13730-026-01142-1
Vancouver
Yamada S, Enomoto S, Matsuo K, Sonezaki Y, Torisu K. Denosumab increased bone mineral density but caused marked serum calcium fluctuations in a patient undergoing peritoneal dialysis. CEN Case Reports. 2026;15(4). doi:10.1007/s13730-026-01142-1
BibTeX
@article{Yamada2026,
author = {Yamada, Shunsuke and Enomoto, Soma and Matsuo, Kana and Sonezaki, Yusuke and Torisu, Kumiko},
title = {Denosumab increased bone mineral density but caused marked serum calcium fluctuations in a patient undergoing peritoneal dialysis},
journal = {CEN Case Reports},
year = {2026},
volume = {15},
number = {4},
doi = {10.1007/s13730-026-01142-1}
}
EUVIMED